Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (117)	10/4/1999 9:25:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 478

Monday October 4, 8:02 am Eastern Time Company Press Release SOURCE: CuraGen Corporation CuraGen and Glaxo Wellcome Collaborate in Alzheimer's Disease Research NEW HAVEN, Conn., Oct. 4 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN - news), an integrated genomics-based drug discovery and development company, in collaboration with Glaxo Wellcome (NYSE: GLX - news), announced today completion of a research program investigating biological pathways that may be associated with Alzheimer's disease. Research into metabolic pathways may help to advance the understanding of this complex disorder, and assist in the search for drug targets and novel markers from which to develop new therapeutics and diagnostic tests for combating this debilitating illness. The completion of the research triggers an undisclosed payment to CuraGen. ''CuraGen's ability to precisely evaluate differential gene expression in specific tissues has provided Glaxo Wellcome with greater insight into Alzheimer's disease,'' stated Allen D. Roses, M.D., Vice President and Worldwide Director of Genetics for Glaxo Wellcome. ''This research further validates CuraGen's functional genomics technologies,'' said Jonathan M. Rothberg, Ph.D. Founder, Chairman, and CEO of CuraGen Corporation. ''This is an important example of CuraGen's ability to enhance our collaborators' efforts in understanding complex diseases, and in identifying targets for which to develop more efficacious drugs.'' GeneCalling(TM), CuraGen's patented technology for precisely identifying and analyzing the differences in gene expression was used to identify patterns of gene expressions in transgenic mice containing the human ApoE gene. Allelic variants of ApoE have been previously associated with the development of Alzheimer's disease. Alzheimer's disease is a chronic neurodegenerative disease characterized by selective neuronal damage resulting in loss of memory and other cognitive abilities. In the U.S. alone it is estimated that approximately four million people suffer from this age-related brain disorder, costing the nation more than $100 billion annually. Over 360,000 people are diagnosed with Alzheimer's disease each year, rendering this disease a significant and costly health problem. Currently, there are no drugs or treatment regimens to cure Alzheimer's disease; existing drugs provide some symptomatic relief in select patients, but do not alter disease progression. About CuraGen Corporation CuraGen Corporation is revolutionizing the discovery and development of pharmaceutical and life science products through the systematic application of genomics. CuraGen's fully integrated, Internet-based genomics technologies, services, and information systems are designed to rapidly generate comprehensive information about human genetic variations, gene expression, biological pathways, and potential products that affect these pathways. CuraGen's research collaborators include Biogen (BGEN), COR Therapeutics (CORR), Genentech (DNA), Glaxo Wellcome (GLX), Hoffmann-La Roche, and Pioneer Hi-Bred International (PHB). The Company employs over 300 people and is headquartered in New Haven, CT, with additional facilities in Branford, CT and Alachua, FL. Additional Company information is available at www.curagen.com. About Glaxo Wellcome Glaxo Wellcome Inc., based in Research Triangle Park, NC, is one of the nation's leading research-based pharmaceutical firms. A subsidiary of London- based Glaxo Wellcome plc, the company is committed to fighting disease by bringing innovative medicines and services to patients and to the healthcare providers who serve them. This release may contain forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the Company's early stage of development, technological uncertainty and product development risks, uncertainty of additional funding, reliance on research collaborations, competition, the Company's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights. SOURCE: CuraGen Corporation